Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from January 2, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 2, 2026 — -28.2% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$50.00 – $51.80Entry zone — fair-value band

$51.50Published — price the day we called it

$57.68Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$36.98Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 4 days.

At window close

-28.2%

realized, from the publication price to the last close inside the window

Peak gain

+24.6%

peak, from the publication price — not a realized return

S&P 500, same window

-3.7%

SPY over the identical days, dividend-adjusted

Window close

$36.98

last close inside the window, ended April 2, 2026

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Days to target

The thesis — published January 2, 2026

Predicted growth

+12%

over the measurement window

Target price

$57.68

the price the thesis aimed for

Entry zone

$50.00 – $51.80

the fair-value band we waited for

Price at publication

$51.50

published January 2, 2026

Confidence

62%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

This is a short-term trade idea driven by news. Approval of an oral Wegovy drug sent the stock up sharply, which can keep momentum going. But a manager selling shares the next day shows people can change their minds quickly. The plan is cautious: buy only small amounts if the price pulls back a bit and avoid getting too large into headline-driven moves.

Primary drivers

FDA approval headline gives a clear near-term news boost
Strong position in GLP-1 drugs keeps investor interest high
A large manager selling shows two-way trading risk
Entering on small pullbacks helps avoid headline whipsaws

How it played out

NVO: target reached in 4 days

Lyra published NVO at 51.5 on 2026-01-02 as a short-term trade idea with 12% expected growth. The thesis pointed to the FDA approval headline for oral Wegovy, continued investor interest in GLP-1 drugs, the risk shown by a large manager selling, and a cautious entry on small pullbacks.

Inside the window, the stock reached the 57.68 target in 4 days. It later peaked at 64.16 on 2026-01-23, a 24.6% gain. By 2026-04-02 it had fallen to 36.98. The published upside thesis played out early, even though the stock ended well below the entry price.

What happened during the window

On 2026-01-05, Novo Nordisk launched the oral Wegovy pill in the U.S., with availability at more than 70,000 pharmacies. On 2026-02-03, the company said adjusted sales were expected to decline between 5% and 13% in 2026 at constant exchange rates.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals